Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 6.1K citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

Peter Malfertheiner, Françis Mégraud, C O'Morain et al. · Gut · 2006 · 2.2K citations · Full text

Medicine, Infectious Diseases, Internal Medicine +17

Management of <i>Helicobacter pylori</i> infection: the Maastricht VI/Florence consensus report

Peter Malfertheiner, Françis Mégraud, Theodore Rokkas et al. · Gut · 2022 · 1.4K citations · Full text

Medicine, Infectious Diseases, Microbiology +16

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Yuichi Sakurai, Yujiro Mori, Hiroyuki Okamoto et al. · Alimentary Pharmacology & Therapeutics · 2015 · 379 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Helen Jenkins, Yuichi Sakurai, Akira Nishimura et al. · Alimentary Pharmacology & Therapeutics · 2015 · 307 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8